Latest Research Study on Biosimilar Market
The Global Biosimilars Market reached USD 30.1 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 76.7 billion by 2031. The global biosimilars market is expected to exhibit a CAGR of 12.8% during the forecast period 2024-2031.
A Biosimilar is a biologic product that is highly similar to an already approved reference biologic in terms of its structure, efficacy, and safety, with no clinically meaningful differences. These products are developed to be used in place of existing biologics but come at a significantly lower cost, making them more accessible to patients. Biosimilars are used to treat a wide range of conditions, including cancer, autoimmune diseases, and other chronic health issues. They offer a cost-effective alternative for healthcare systems while maintaining the same therapeutic benefits as the original biologic.
The development of biosimilars is regulated by health authorities like the FDA and EMA to ensure their safety and efficacy, providing patients with trusted treatment options at a reduced cost.
Download Free Sample PDF: https://www.datamintelligence.com/download-sample/biosimilars-market
Market Growth Drivers:
The rising number of biosimilar drug approvals by the FDA drives global biosimilar market growth.
The growing number of approved biosimilars, driven by improved FDA review processes and advancements in manufacturing and development techniques, is expected to accelerate the biosimilars market. For example, in March 2022, Amneal Pharmaceuticals received FDA approval for its biosimilar, filgrastim-ayow, which is a substitute for Neupogen. The drug will be sold under the RELEUKO brand. Additionally, the increased familiarity of manufacturers with the intricate regulatory and legal requirements for biosimilar applications has led to a rise in biosimilar submissions.
The time and cost of biosimilar drug development hamper global biosimilar market growth.
The high cost and lengthy development timeline of biosimilar drugs present major challenges for the market, affecting growth and profitability. Developing a biosimilar requires 7 to 8 years and costs between $100 million and $300 million, making it a costly investment. These substantial research and production expenses limit accessibility, particularly in low-income regions, slowing adoption rates. As a result, the high development costs will remain a key barrier to market expansion in the coming years.
Market Segments:
- By Product: Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Insulin, Anti-coagulants, Erythropoietin, Fusion Proteins, Granulocyte Colony Stimulating Factor, Follitropin, Others
- By Technology: Recombinant DNA Technology (rDNA technology), Monoclonal Antibodies (MAb) Technology
- By Application: Oncology, Chronic and Immune Diseases, Infectious Diseases, Growth Hormone Deficiency, Blood Disorders, Others
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
- By Region: North America, Latin America, Europe, Asia Pacific, Middle East and Africa
Top Key Players:
- Monoclonal Antibodies
- Recombinant Human Growth Hormone (rhGH)
- Insulin
- Anti-coagulants
- Erythropoietin
- Fusion Proteins
Customize Your Scope: https://www.datamintelligence.com/download-sample/biosimilars-market
Regional Growth
North America holds a dominant position in the global biosimilars market.
North America is projected to account for approximately 38.1% of the total market share throughout the forecast period. This growth is driven by an aging population, a well-established healthcare infrastructure, rising cases of diseases like cancer, and increasing FDA approvals for biosimilar drugs. Additionally, government initiatives aimed at strengthening the healthcare system are expected to further propel regional market expansion.
For example, in January 2023, biopharmaceutical company Amgen introduced a biosimilar version of Humira in the U.S., offering a more affordable alternative for patients with conditions such as psoriasis, arthritis, and Crohn’s disease. This launch provides a lower-cost option for a treatment that typically costs around $90,000 per year.
Key Development
In May 2023, Gulf Pharmaceutical Industries PJSC (Julphar), one of the largest pharmaceutical manufacturers in the Middle East and Africa (MEA), announced a strategic licensing agreement with Sunshine Lake Pharma, a Chinese pharmaceutical company. This partnership positions Julphar as the first manufacturer of modern insulin biosimilars in the MENA region, marking a significant milestone in advancing diabetes treatment accessibility.
